TNFSF11 and arthritic joint disease: Thus, administration of osteoprotegerin, which prevents the binding of RANKL to RANK, decreased arthritis-induced bone loss [65], suggesting that TZDs may prevent bone loss, at least in part, by decreasing the production of inflammatory cytokines in inflamed synovium.